Luseogliflozin

Last updated
Luseogliflozin
Luseogliflozin structure.svg
Clinical data
Trade names Lusefi
Other namesTS-071
ATC code
Legal status
Legal status
  • Rx-only in Japan
Identifiers
  • (2S,3R,4R,5S,6R)-2-{5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl}-6-(hydroxymethyl)thiane-3,4,5-triol
CAS Number
PubChem CID
DrugBank
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C23H30O6S
Molar mass 434.55 g·mol−1
3D model (JSmol)
  • CCOc1ccc(Cc2cc([C@@H]3S[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2C)cc1
  • InChI=1S/C23H30O6S/c1-4-29-16-7-5-14(6-8-16)10-15-11-17(18(28-3)9-13(15)2)23-22(27)21(26)20(25)19(12-24)30-23/h5-9,11,19-27H,4,10,12H2,1-3H3/t19-,20-,21+,22-,23+/m1/s1
  • Key:WHSOLWOTCHFFBK-ZQGJOIPISA-N

Luseogliflozin (trade name Lusefi) is a pharmaceutical drug (an SGLT2 inhibitor) used for the treatment of type 2 diabetes mellitus. [1] [2] It was approved for use in Japan in 2014. [1] In a meta-analysis involving data from 10 randomized controlled trials (1304 patients), Dutta et. al. demonstrated the good glycaemic efficacy (mean glycated hemoglobin reduction of -0.76% and mean fasting glucose reduction of -26.69mg/dl) and safety of luseogliflozin 2.5mg/day as compared to placebo. Additional benefits include significant reduction in systolic blood pressure (-4.19 mm Hg), serum triglycerides (-12.60mg/dl), uric acid (-0.48mg/dl) and alanine aminotransferase (-4.11 IU/L) as compared to placebo, highlighting the beneficial impact on the different aspects of metabolic syndrome. [3]

References

  1. 1 2 Markham A, Elkinson S (June 2014). "Luseogliflozin: first global approval". Drugs. 74 (8): 945–50. doi:10.1007/s40265-014-0230-8. PMID   24848756. S2CID   1770988.
  2. ↑ Samukawa Y, Sata M, Furihata K, Ito T, Ueda N, Ochiai H, et al. (September 2017). "Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study". Clinical Pharmacology in Drug Development. 6 (5): 439–447. doi: 10.1002/cpdd.364 . PMID   28783873.
  3. ↑ Dutta D, Kadian J, Mahajan K, Dhall A, Sharma M (Mar 2023). "Efficacy and safety of luseogliflozin in improving glycaemic and non-glycaemic outcomes in type-2 diabetes: A meta-analysis". Diabetes Metab Syndr. 17 (3) 102742. doi:10.1016/j.dsx.2023.102742. PMID   36933330.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.